Newsfilter article unlocker

We do need to keep in mind that this is after only a single cycle of treatment. Based on the most commonly cited historical trials, you'd normally expect to see high DAC monotherapy, that's our control arm, deliver a 17 to 18 percent CR rate. But in those trials, trials, patients received multiple cycles. Considering that this trial measures performance after only one cycle, this outcome is right in line with expectations. And likewise, the animis and test arm results are a little lower than our phase two data, but again, our phase two trial allowed multiple cycles, so this outcome based on just a single cycle is not only very strong, it's right in line with expectations as well. And when you look at the makeup of the first 45 subjects, the data just look even stronger. And more than 75% of the subjects were over age 60, which is in the demographic sweet spot for AML. And it speaks to the improved tolerability of anamycin compared with existing therapies.